Kuwanon-L as a New Allosteric HIV-1 Integrase Inhibitor: Molecular Modeling and Biological Evaluation (Q35770636)

10 August 2017

Kuwanon-L as a New Allosteric HIV-1 Integrase Inhibitor: Molecular Modeling and Biological Evaluation (English)

1 reference

10 August 2017

1 reference

5

Zeger Debyser

0 references

Riccardo Martini

Riccardo Martini

3

0 references

Andrea Calcaterra

Andrea Calcaterra

10

0 references

Francesca Esposito

Francesca Esposito

1

0 references

Filippo Canducci

Filippo Canducci

14

0 references

Angela Corona

Angela Corona

8

0 references

Frauke Christ

4

Frauke Christ

1 reference

10 August 2017

13

Massimo Clementi

1 reference

10 August 2017

15

Maurizio Botta

1 reference

10 August 2017

9

Elisa Rita Ceresola

1 reference

10 August 2017

2

Cristina Tintori

1 reference

10 August 2017

6

Roberto Ferrarese

1 reference

10 August 2017

Gianluigi Cabiddu

7

1 reference

10 August 2017

Valentina Iovine

11

1 reference

10 August 2017

Bruno Botta

12

1 reference

10 August 2017

Enzo Tramontano

16

1 reference

10 August 2017

11 September 2015

1 reference

10 August 2017

1 reference

10 August 2017

16

1 reference

10 August 2017

17

1 reference

10 August 2017

2507-2512

1 reference

Past and future. Current drugs targeting HIV-1 integrase and reverse transcriptase-associated ribonuclease H activity: single and dual active site inhibitors

10 August 2017

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.201500385

Relationship between the oligomeric status of HIV-1 integrase on DNA and enzymatic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.201500385

Identification of the LEDGF/p75 HIV-1 integrase-interaction domain and NLS reveals NLS-independent chromatin tethering

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.201500385

Allosteric inhibitor development targeting HIV-1 integrase

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.201500385

Small-molecule inhibitors of the LEDGF/p75 binding site of integrase block HIV replication and modulate integrase multimerization

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.201500385

LEDGINs, non-catalytic site inhibitors of HIV-1 integrase: a patent review (2006 - 2014).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.201500385

Multimode, Cooperative Mechanism of Action of Allosteric HIV-1 Integrase Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.201500385

Rational design of small-molecule inhibitors of the LEDGF/p75-integrase interaction and HIV replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.201500385

Fragment-based design of ligands targeting a novel site on the integrase enzyme of human immunodeficiency virus 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.201500385

Crystal structure of the HIV-1 integrase core domain in complex with sucrose reveals details of an allosteric inhibitory binding site

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.201500385

Investigation on the sucrose binding pocket of HIV-1 Integrase by molecular dynamics and synergy experiments

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.201500385

Hypericum hircinum L. components as new single-molecule inhibitors of both HIV-1 reverse transcriptase-associated DNA polymerase and ribonuclease H activities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.201500385

From the traditional Chinese medicine plant Schisandra chinensis new scaffolds effective on HIV-1 reverse transcriptase resistant to non-nucleoside inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.201500385

Natural product and natural product derived drugs in clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.201500385

Natural products: a continuing source of novel drug leads

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.201500385

Allosteric inhibition of HIV-1 integrase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.201500385

An allosteric mechanism for inhibiting HIV-1 integrase with a small molecule

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.201500385

Development and testing of a general amber force field

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.201500385

Fast, efficient generation of high-quality atomic charges. AM1-BCC model: II. Parameterization and validation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.201500385

Numerical integration of the cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.201500385

Langevin modes of macromolecules: applications to crambin and DNA hexamers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.201500385

Langevin dynamics of peptides: the frictional dependence of isomerization rates of N-acetylalanyl-N'-methylamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.201500385

Genotypic/phenotypic patterns of HIV-1 integrase resistance to raltegravir.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.201500385

Cross-resistance Profile of the Novel Integrase Inhibitor Dolutegravir (S/GSK1349572) Using Clonal Viral Variants Selected in Patients Failing Raltegravir

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCBIC.201500385

21 January 2018

Identifiers

DOI

10.1002/CBIC.201500385

1 reference

10 August 2017

1 reference